Skip to main content Skip to search Skip to main navigation

ICH: Press Release ICH-Assembly Meeting

The ICH published a press release on June 20, regarding a face-to-face meeting on June 12 and 13, 2023, in Vancouver, Canada. Meetings of 14 working groups, the ICH Management Committee and the MedDRA Management Committee were also held during that time.

New Areas of ICH Harmonisation

Three new areas of harmonisation were defined at the meeting:

  • “General Considerations for Patient Preference Studies” – Efficacy guideline with considerations for a systematic approach to planning, conducting, analyzing, and processing patient preference studies when they contain important advanced information for evaluating products or inform drug development and related decisions.
  • “Nonclinical Safety Studies for Oligonucleotide-based Therapeutics” – Safety Guideline that communicates regulatory requirements for non-clinical safety evaluations of various oligonucleotide-based treatment options through general understanding.
  • “Bioequivalence for Modified-Release Products” – Multidisciplinary Guideline that represents an important step towards the harmonisation of bioequivalence standards for more complex dosage forms. The harmonised elements of the M13 Guideline series are transferable.

In a later step, the starting timeframe will be defined.

Additional results of the meeting are:

  • The formation of a new ICH “Cell and Gene Therapies” Discussion Group (CGTDG), providing a technical communication forum for issues related to ICH harmonisation efforts in the area of CGT products.
  • A new ICH Reflection Paper for the “International Harmonisation of Real-World Evidence Terminology and Convergence of General Principles Regarding Planning and Reporting of Studies Using Real-World Data, with a Focus on Effectiveness of Medicines”.
  • They noted significant milestones since the last ICH meeting, for example the adoptation of the revised ICH Q9 (R1) Guideline on “Quality Risk Management” in January 2023.

The press release also states that the African Authority EDA (Egypt) has joined ICH as a Member and NAFDAC (Nigeria) as an ICH Observer.


Source

ICH: Press Release

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
 Data Integrity and Data Governance

Data Integrity and Data Governance

Data integrity is a key element in the pharmaceutical quality assurance system which has gained importance in recent years, especially from the viewpoint of the authorities. In GxP-regulated companies, managers are responsible for identifying and minimising risks to data integrity (“data governance”).

Read more
EMA Clarifies “Novel or Complex Manufacturing Process” Definition

EMA Clarifies “Novel or Complex Manufacturing Process” Definition

In its Quality of Medicines Q&A – Part 1, the EMA has clarified how “novel or complex manufacturing processes” should be interpreted for variation categories Q.II.b.1 (new/replacement finished product manufacturing site) and Q.II.b.4 (change in batch size).
Read more
EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.
Read more
Previous
Next